# Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

> **NCT00597597** · PHASE2 · TERMINATED · sponsor: **Rush University Medical Center** · enrollment: 11 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00597597
- **Lead sponsor:** Rush University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-04
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** not enough patients enrolled
- **Last updated:** 2023-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00597597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00597597, "Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00597597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*